Caisse de depot et placement du Quebec purchased a new stake in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,730 shares of the medical instruments supplier's stock, valued at approximately $2,775,000.
Several other large investors have also bought and sold shares of WST. Wealth Alliance LLC grew its stake in shares of West Pharmaceutical Services by 3.8% in the 1st quarter. Wealth Alliance LLC now owns 945 shares of the medical instruments supplier's stock worth $237,000 after acquiring an additional 35 shares in the last quarter. IFM Investors Pty Ltd raised its holdings in shares of West Pharmaceutical Services by 0.3% in the first quarter. IFM Investors Pty Ltd now owns 13,773 shares of the medical instruments supplier's stock valued at $3,452,000 after purchasing an additional 43 shares during the last quarter. Compound Planning Inc. lifted its position in shares of West Pharmaceutical Services by 3.6% during the first quarter. Compound Planning Inc. now owns 1,224 shares of the medical instruments supplier's stock valued at $307,000 after purchasing an additional 43 shares in the last quarter. Aptus Capital Advisors LLC boosted its holdings in West Pharmaceutical Services by 5.5% during the fourth quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier's stock worth $249,000 after purchasing an additional 47 shares during the last quarter. Finally, Cornerstone Planning Group LLC grew its position in West Pharmaceutical Services by 90.9% in the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 50 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors.
West Pharmaceutical Services Price Performance
Shares of NYSE:WST opened at $338.21 on Friday. The firm has a market capitalization of $23.80 billion, a PE ratio of 43.30, a P/E/G ratio of 2.36 and a beta of 1.15. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average price of $350.55 and a two-hundred day moving average price of $303.61. West Pharmaceutical Services, Inc. has a twelve month low of $223.83 and a twelve month high of $386.00.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts' consensus estimates of $2.08 by $0.29. The company had revenue of $872.30 million for the quarter, compared to analysts' expectations of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. West Pharmaceutical Services's revenue was up 13.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current year.
West Pharmaceutical Services Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services's dividend payout ratio (DPR) is presently 11.27%.
Wall Street Analyst Weigh In
A number of analysts recently commented on the company. Zacks Research downgraded West Pharmaceutical Services from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 12th. Citigroup upped their price objective on West Pharmaceutical Services from $400.00 to $412.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Morgan Stanley lifted their target price on West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 9th. Evercore reissued an "outperform" rating and issued a $425.00 price target on shares of West Pharmaceutical Services in a report on Monday, July 27th. Finally, KeyCorp increased their price target on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an "overweight" rating in a research report on Thursday, July 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, West Pharmaceutical Services has a consensus rating of "Moderate Buy" and a consensus target price of $368.08.
Check Out Our Latest Report on West Pharmaceutical Services
About West Pharmaceutical Services
(
Free Report)
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
Recommended Stories
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
